BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29415891)

  • 1. Efficacy of intracellular immune checkpoint-silenced DC vaccine.
    Wang D; Huang XF; Hong B; Song XT; Hu L; Jiang M; Zhang B; Ning H; Li Y; Xu C; Lou X; Li B; Yu Z; Hu J; Chen J; Yang F; Gao H; Ding G; Liao L; Rollins L; Jones L; Chen SY; Chen H
    JCI Insight; 2018 Feb; 3(3):. PubMed ID: 29415891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors.
    Yan CH; Wang JZ; Liu DH; Xu LP; Chen H; Liu KY; Huang XJ
    Eur J Haematol; 2013 Oct; 91(4):304-14. PubMed ID: 23837640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature.
    Saito S; Yanagisawa R; Yoshikawa K; Higuchi Y; Koya T; Yoshizawa K; Tanaka M; Sakashita K; Kobayashi T; Kurata T; Hirabayashi K; Nakazawa Y; Shiohara M; Yonemitsu Y; Okamoto M; Sugiyama H; Koike K; Shimodaira S
    Cytotherapy; 2015 Mar; 17(3):330-5. PubMed ID: 25484308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse.
    Martelli MF; Di Ianni M; Ruggeri L; Falzetti F; Carotti A; Terenzi A; Pierini A; Massei MS; Amico L; Urbani E; Del Papa B; Zei T; Iacucci Ostini R; Cecchini D; Tognellini R; Reisner Y; Aversa F; Falini B; Velardi A
    Blood; 2014 Jul; 124(4):638-44. PubMed ID: 24923299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-α: A Potentially Effective Treatment for Minimal Residual Disease in Acute Leukemia/Myelodysplastic Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation.
    Mo XD; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YH; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1939-47. PubMed ID: 26116088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.
    Jung SH; Lee HJ; Lee YK; Yang DH; Kim HJ; Rhee JH; Emmrich F; Lee JJ
    Oncotarget; 2017 Jun; 8(25):41538-41548. PubMed ID: 28088784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
    Pyzer AR; Avigan DE; Rosenblatt J
    Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
    Subklewe M; Geiger C; Lichtenegger FS; Javorovic M; Kvalheim G; Schendel DJ; Bigalke I
    Cancer Immunol Immunother; 2014 Oct; 63(10):1093-103. PubMed ID: 25186611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4
    Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z
    Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.
    Grabrucker C; Liepert A; Dreyig J; Kremser A; Kroell T; Freudenreich M; Schmid C; Schweiger C; Tischer J; Kolb HJ; Schmetzer H
    J Immunother; 2010 Jun; 33(5):523-37. PubMed ID: 20463595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful cell-mediated cytokine-activated immunotherapy for relapsed acute myeloid leukemia after hematopoietic stem cell transplantation.
    Gesundheit B; Shapira MY; Resnick IB; Amar A; Kristt D; Dray L; Budowski E; Or R
    Am J Hematol; 2009 Mar; 84(3):188-90. PubMed ID: 19105234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.
    Yegin ZA; Ozkurt ZN; Aki SZ; Sucak GT
    Transfus Apher Sci; 2010 Jun; 42(3):239-45. PubMed ID: 20385512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia.
    Ruggeri A; Labopin M; Sanz G; Piemontese S; Arcese W; Bacigalupo A; Blaise D; Bosi A; Huang H; Karakasis D; Koc Y; Michallet M; Picardi A; Sanz J; Santarone S; Sengelov H; Sierra J; Vincent L; Volt F; Nagler A; Gluckman E; Ciceri F; Rocha V; Mohty M; ;
    Leukemia; 2015 Sep; 29(9):1891-900. PubMed ID: 25882700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia.
    Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q
    J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial.
    Van Driessche A; Van de Velde AL; Nijs G; Braeckman T; Stein B; De Vries JM; Berneman ZN; Van Tendeloo VF
    Cytotherapy; 2009; 11(5):653-68. PubMed ID: 19530029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.